Lv42
426 积分 2023-01-11 加入
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
2小时前
已完结
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer
3小时前
已完结
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments
1天前
已完结
The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single-arm meta-analysis
3天前
已完结
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma
7天前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
14天前
已完结
https://www.nature.com/articles/s41557-024-01507-y
17天前
已完结
Non-animal photosafety screening for complex cosmetic ingredients with photochemical and photobiochemical assessment tools
20天前
已关闭
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
22天前
已完结
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis
23天前
已完结
皖公网安备34019202002308
